Master Institute of Education President Antônio Carlos, Avenida Minas Gerais, 1889 - Centro, Araguari, MG, 38.440-046, Brazil.
Department of Clinical Research, Federal University of Uberlândia, Uberlândia, MG, Brazil.
Curr Atheroscler Rep. 2018 Feb 8;20(2):9. doi: 10.1007/s11883-018-0708-z.
This clinical update is intended to focus in relationship between HIV infection and use of antiretroviral therapy (ART) and statin.
Though ART significantly changed the course of HIV infection, it is related to numerous side effects principally to the lipid profile. In this way, statins became one of the most used lipid-lowering therapies in this population. In our clinical update, we evaluated studies that demonstrate the relationship and molecular mechanisms that HIV infection and ART use trigger dyslipidemia and also the use of statin to reduce this condition. We have demonstrated that use of statin can be used in dyslipidemic HIV-infected people as long as there is no drug interaction with ART. Recently, studies using rosuvastatin have shown greater effects when compared to the other statins.
本临床更新旨在关注 HIV 感染与抗逆转录病毒治疗（ART）和他汀类药物的使用之间的关系。
尽管 ART 极大地改变了 HIV 感染的进程，但它与许多副作用有关，主要与脂质谱有关。因此，他汀类药物成为该人群中使用最多的降脂药物之一。在我们的临床更新中，我们评估了表明 HIV 感染和 ART 使用引发血脂异常的关系和分子机制的研究，以及使用他汀类药物来降低这种情况的研究。我们已经证明，只要与 ART 没有药物相互作用，他汀类药物可用于血脂异常的 HIV 感染者。最近，使用瑞舒伐他汀的研究表明，与其他他汀类药物相比，其效果更大。
